Biogen Inc.
BIIBNASDAQHealthcareDrug Manufacturers - General
As of Oct 23, 2026 close
- Market cap
- $37.28B
- P/E (TTM)
- 44.64
- Forward P/E
- 82.30
- Dividend yield
- -
- 52-week range
- $138.00$244.65
- Volume (live)
- -
- Avg. volume (3M)
- 1.23M
Biogen (BIIB) Stock Price & Financial Analysis
Biogen Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $246.15 - $252.44 |
|---|---|
| 52-Week High | $244.65 |
| 52-Week Low | $138.00 |
| Open | $251.68 |
| Volume (last close) | 1.15M |
| Average Volume (3M) | 1.23M |
| Revenue (TTM) | 10.03B |
|---|---|
| Net Income (TTM) | 835.09M |
| Free Cash Flow (TTM) | 2.65B |
| EPS (TTM) | $5.65 |
| Profit Margin | 8.33% |
| Operating Margin | 11.08% |
| Return on Equity (ROE) | 4.43% |
| Debt to Equity | 0.43 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Last Dividend Ex-Date | Feb 2, 2017 |
| Market Cap | 37.28B |
|---|---|
| Shares Outstanding | 148.70M |
| P/E Ratio (TTM) | 44.64 |
| Forward P/E | 82.30 |
| Price to Sales (P/S) | 3.72 |
| Price to Book (P/B) | 1.98 |
| EV/EBITDA | 15.43 |
| 50-Day MA | $220.94 |
|---|---|
| 200-Day MA | $198.44 |
| 1-Year Change | +69.14% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Biogen at a Glance
As of the Oct 23, 2026 close, Biogen (BIIB) has a market capitalization of $37.28B. The stock trades at 44.6× trailing earnings, 82.3× forward earnings and 3.7× sales. Over the trailing twelve months it earned $835.09M on revenue of $10.03B (a 8.3% profit margin) and generated $2.65B of free cash flow. Revenue grew 0.3% year over year.
As of its latest reported balance sheet, it holds $1.28B in cash and securities against $8.09B of debt, a net debt position of $6.81B.
Biogen does not currently pay a dividend.
The share price is up 69.1% over the past year. At $250.69 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $138.00 to $244.65, above its 200-day moving average of $198.44.
Based on 28 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $244.70, 2.4% below the Oct 23, 2026 close.
Frequently Asked Questions About Biogen
What is the current stock price for BIIB?
As of the Oct 23, 2026 close, BIIB stock trades at $250.69. The 52-week range is $138.00–$244.65, with a day range of $246.15–$252.44.
What is the P/E ratio for BIIB?
As of the Oct 23, 2026 close, Biogen's trailing twelve-month (TTM) P/E ratio is 44.6, meaning investors pay $44.6 for every $1 of annual earnings. The forward P/E is 82.3, reflecting analyst expectations for future earnings. Biogen operates in the Healthcare sector.
Does BIIB pay dividends?
Biogen does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for BIIB?
Based on ratings from 28 professional analysts over the last 90 days, the consensus for BIIB is Buy. The average 12-month price target is $244.70, a 2.4% downside from the Oct 23, 2026 close of $250.69.
What is the market cap of BIIB?
As of the Oct 23, 2026 close, Biogen's market capitalization is $37.28B, classifying it as a large-cap company. Biogen operates in the Healthcare sector within the Drug Manufacturers - General industry.